Tessari Eben's Form 4 filing
Kiniksa Pharmaceuticals International, plc (KNSA) · filed Dec 1, 2025
- Accession no.
- 0001867899-25-000011
- Filed
- Dec 1, 2025
- Trade date
- Nov 26, 2025
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $8.58K. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Tessari EbenCIK 0001867899 | Officer (CHIEF OPERATING OFFICER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 26, 2025 | Class A Ordinary Share | MOption exerciseAcquired | +200 | $22.89 | +$4,578 | 22,914 | Direct | |
| Nov 26, 2025 | Class A Ordinary Share | SSaleDisposed | −200 | $42.89 | −$8,578 | 22,714 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 26, 2025 | Class A Ordinary Share | MOption exerciseDisposed | −200 | $0.00 | $0 | 46,938 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.